Leaps by Bay­er backs a pro­tein en­gi­neer­ing start­up tak­ing on Aim­mune — and Nestlé — in peanut al­ler­gy

Lit­tle cap­sules of peanut pow­der drove Nestlé’s $2.6 bil­lion buy­out of Aim­mune. Now, with $40 mil­lion in new fund­ing, a fledg­ling biotech is promis­ing to bring a more so­phis­ti­cat­ed ver­sion of that pro­tein ther­a­py that can go much, much fur­ther.

Ukko’s goal is two-pronged — with the ini­tial prod­ucts span­ning ther­a­peu­tic and food — but it’s ground­ed in the same pro­tein en­gi­neer­ing plat­form, co-founder and CEO Anat Bin­ur told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER